| Definitions and outcomes
Cytomegalovirus viremia was defined as the detection of virus DNA above the threshold level of 400 copies/mL in a blood sample. In studies published after 2010, CMV disease was defined according to the definitions of "The Third International Consensus Guidelines on the Management of CMV in Solid Organ Transplantation". 16 Accordingly, CMV syndrome, which is CMV viremia with compatible symptoms or CMV tissue-invasive disease documented by molecular or histopathologic studies at the tissue level, was categorized as CMV disease. Acute graft rejection was defined as biopsy-proven acute rejection (BPAR), and graft loss was defined as a return of the patient to conditions before the transplantation regarding renal function.
The outcomes of this study were CMV disease, BPAR, and graft loss among kidney transplant patients who received universal prophylaxis or the preemptive approach to protect against CMV reactivation.
| Data extraction
The frequency of CMV disease, BPAR, and graft loss in both arms was extracted from tables or the text of eligible studies either directly or by calculating from the given percentages. No data were obtained from plots. We included only the recent outcome rates from studies with more than one follow-up period. Two investigators individually checked all outcome rates twice.
The CMV serostatus of the transplant recipients and the study type (RCT vs observational study) were extracted as potential moderators of homogeneity between the studies.
| Statistical methods
All statistical analyses were performed using the packages meta, metafor, and metagear in the open source platform R. 17, 18 We analyzed the data used in this study as rare events data.
One study had zero events; others had one or only few events. In rare events data, small changes have the potential to distort variances and the direction of effect sizes. Rare and zero events data therefore need to be analyzed and pooled with special measures to minimize bias on weights. Therefore, we constructed random effects models using the Paule-Mandel estimator to assess between-study variances and the associated uncertainties. 19, 20 We used the MantelHaenszel method without continuity correction to estimate effect sizes. 21 Finally, we used an absolute measure, risk difference (RD), to pool the effect estimates. The RD has some advantages for rare events data as it does not require zero-cell corrections and can be simply converted to the number needed to treat (NNT). One divided by the RD provides the NNT, which is a straightforward scale that can be used by physicians to interpret rare events. 22 Between-study heterogeneity was assessed with the I 2 statistics and is presented as forest plots. We conducted sensitivity analysis using a leave-one-out test. Publication bias was assessed by funnel plots. The Egger test was used to determine plot asymmetry. Where required, meta-regression models with potential moderators were used to assess the source of heterogeneity.
Meta-regression test was performed via metareg function of the meta package.
| RE SULTS
We retrieved 378 titles from the databases; no unpublished data were identified. After excluding duplicates, 250 studies were further evaluated. Studies that received ≥2 adverse decisions from the investigators were excluded, leaving 34 full-text articles. Among the full text articles, 23 were excluded due to following reasons. One study had been conducted twice; thus, the earlier version was excluded. 23 One study was excluded as it was in a pediatric population and another one as it was a meta-analysis. Two studies were excluded because we could not extract data. The other excluded studies either had a quasiexperimental or sequential design where the baseline characteristics of study arms could not be compared or the design did not include two arms. Finally, 11 studies were found to be eligible ( Figure 1 ).
Overall, the quality of data was low to moderate ( Figure S1 ). All
RCTs were open-label and except one neither had adequately randomized. Therefore, we assessed risk of bias among RCTs as high.
Observational studies obtained scores between 5 and 7, and thus,
we considered risk of bias as moderate. However, we admit that our assessments do not necessarily represent the exact level of quality of these studies.
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Table1 presents the features of the 11 studies that were included in the final analysis. Five studies were open-label RCTs. [25] [26] [27] [28] [29] Of the observational studies, five had a retrospective cohort design 10,30-33 and one a prospective cohort design. 34 Four RCTs and one observational study included both CMV-seropositive and -seronegative recipients, while the others restricted the study populations to only seropositive recipients. Of note, studies published in 2010 or later included only seropositive recipients. The follow-up duration varied across studies (from 1 to 7 years).
We presented details of studies in Table S1 . Briefly, only three studies presented data for CMV syndrome while others gave combined data for CMV disease. All studies used PCR to detect CMV viremia. Three studies used ≥400 copies/mL as threshold while others accepted ≥1000 or ≥2000 copies/mL. Three studies administered prophylactic antiviral drugs for 100 days while others for 3 months.
Except for one study, all others used ganciclovir or valganciclovir either at high or low daily doses.
The data of 10 studies (five RCTs and five observational studies) were analyzed for CMV disease. Because only three studies reported event rates of CMV syndrome, we could not synthesize effects for CMV syndrome alone (Table S1) . [26] [27] [28] The random effects model for CMV disease revealed a significant effect fa- To address variability due to heterogeneity between studies, we constructed meta-regression models by study type and recipient We also pooled effect estimates in subgroups of study types (RCTs and observational studies) (Figure 3 ). In the subgroup of observational studies, the prophylaxis approach performed better on CMV disease (RD = −0.0570; CIs = 0.0823, −0.0317) with a negligible heterogeneity. A subgroup of studies according to quality scores would obtain virtually the same subgroup of study types. Therefore, we consider that subgroup analysis according to study types represent subgroup analysis according to study qualities. 
TA B L E 1 Features of studies included in the final analysis

F I G U R E 2 Forest plot showing the risk differences of strategies for cytomegalovirus (CMV) disease among the subgroup of CMV serostatus
We were able to pool data from all 11 studies for BPAR. The random effects model showed a non-significant pooled estimate (RD = −0.0309; CIs = −0.0697, 0.0080; P-value = 0.1191); the between-study heterogeneity was low (I 2 = 21.8%). Sensitivity analysis indicated one study as an outlier with a negligible effect on the pooled effect direction. After removing, this study from the analysis, 28 the model performed better with minimal variability due to heterogeneity (Figure 4 ).
The data of nine studies were analyzed for graft loss. The pooled effect of these studies showed a non-significant association between the CMV preventive approaches and graft loss ( Figure 5 ). The variability due to heterogeneity was low (I 2 = 0%).
F I G U R E 3
Forest plot showing the risk differences of strategies for cytomegalovirus disease among the subgroup of study types F I G U R E 4 Forest plot for biopsy proven acute rejection F I G U R E 5 Forest plot for graft-loss Figure S2 presents the funnel plot. The linear regression test (Egger test) did not detect a significant asymmetry in the funnel plot, which indicates that publication bias might not be significant.
| D ISCUSS I ON
This meta-analysis revealed a moderate quality of evidence on the effectiveness of prophylaxis vs preemptive therapy for preventing adverse outcomes associated with CMV viremia among kidney transplant patients.
In this study, the RD for CMV disease in the subgroup of studies published after 2010 favored universal prophylaxis over the preemptive approach, with negligible between-study heterogeneity. In the subgroup of studies published before 2010, there was no excess risk between the two CMV preventive approaches.
However, the between-study variability was considerably high, making this finding highly speculative. Similarly, a meta-analysis published in 2011 that included earlier studies did not find a significant association between CMV preventive strategies and CMV disease. 35 In this meta-analysis, the heterogeneity was also considerably high. The heterogeneity between studies published be- We found no significant advantage for either of the CMV preventive strategies regarding BPAR and graft loss. Similarly, a previous meta-analysis found non-significant effects of CMV preventive strategies on BPAR or graft loss among solid organ transplant recipients. 36 Our study showed that universal prophylaxis outperformed the preemptive approach in CMV disease. However, CMV viremia is frequently detected in patients with severe infections, 8 and so one must be skeptical about making a diagnosis of CMV disease in a patient with non-specific symptoms and CMV viremia. Rigorous screening for other infectious etiologies must gain more attention to avoid the misdiagnosis of CMV disease and unnecessary exposure of recipients to highly toxic substances such as ganciclovir.
Most significant limitations of this analysis were that the studies have moderate to high risk of bias and have rare events. Especially, the latter limitation is prone to biased effect estimates and restricts the generalizability of our results.
Since, prophylaxis and the preemptive approach showed a comparable performance regarding serious outcomes such as BPAR and graft-loss and universal prophylaxis had a high NNT value for preventing CMV disease, this study encourages the use of the preemptive approach among kidney transplant recipients. However, the quality of the included studies was not high enough to derive firm recommendations. Future blinded and appropriately randomized studies are needed to confirm this study's findings.
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